These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

476 related items for PubMed ID: 19523908

  • 21. Immunogenicity and reactogenicity of 1 versus 2 doses of trivalent inactivated influenza vaccine in vaccine-naive 5-8-year-old children.
    Neuzil KM, Jackson LA, Nelson J, Klimov A, Cox N, Bridges CB, Dunn J, DeStefano F, Shay D.
    J Infect Dis; 2006 Oct 15; 194(8):1032-9. PubMed ID: 16991077
    [Abstract] [Full Text] [Related]

  • 22. Intanza(®) 15 mcg intradermal influenza vaccine elicits cross-reactive antibody responses against heterologous A(H3N2) influenza viruses.
    Ansaldi F, Canepa P, Ceravolo A, Valle L, de Florentiis D, Oomen R, Vogel FR, Denis M, Samson SI, Icardi G.
    Vaccine; 2012 Apr 16; 30(18):2908-13. PubMed ID: 22342501
    [Abstract] [Full Text] [Related]

  • 23. Trivalent inactivated influenza virus vaccine given to two-month-old children: an off-season pilot study.
    Walter EB, Englund JA, Blatter M, Nyberg J, Ruben FL, Decker MD, GRC27 Study Team.
    Pediatr Infect Dis J; 2009 Dec 16; 28(12):1099-104. PubMed ID: 19935270
    [Abstract] [Full Text] [Related]

  • 24. Randomized Controlled Trial to Compare Immunogenicity of Standard-Dose Intramuscular Versus Intradermal Trivalent Inactivated Influenza Vaccine in HIV-Infected Men Who Have Sex With Men in Bangkok, Thailand.
    Garg S, Thongcharoen P, Praphasiri P, Chitwarakorn A, Sathirapanya P, Fernandez S, Rungrojcharoenkit K, Chonwattana W, Mock PA, Sukwicha W, Katz JM, Widdowson MA, Curlin ME, Gibbons RV, Holtz TH, Dawood FS, Olsen SJ.
    Clin Infect Dis; 2016 Feb 01; 62(3):383-391. PubMed ID: 26486702
    [Abstract] [Full Text] [Related]

  • 25. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain.
    Hung IF, Levin Y, To KK, Chan KH, Zhang AJ, Li P, Li C, Xu T, Wong TY, Yuen KY.
    Vaccine; 2012 Oct 05; 30(45):6427-35. PubMed ID: 22910287
    [Abstract] [Full Text] [Related]

  • 26. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines: effect of composition, spatial organization and immunization route on the immunogenicity in a murine challenge model.
    Hagenaars N, Mastrobattista E, Glansbeek H, Heldens J, van den Bosch H, Schijns V, Betbeder D, Vromans H, Jiskoot W.
    Vaccine; 2008 Dec 02; 26(51):6555-63. PubMed ID: 18848856
    [Abstract] [Full Text] [Related]

  • 27. Antibody responses after dose-sparing intradermal influenza vaccination.
    Auewarakul P, Kositanont U, Sornsathapornkul P, Tothong P, Kanyok R, Thongcharoen P.
    Vaccine; 2007 Jan 08; 25(4):659-63. PubMed ID: 17011678
    [Abstract] [Full Text] [Related]

  • 28. A nasally administered trivalent inactivated influenza vaccine is well tolerated, stimulates both mucosal and systemic immunity, and potentially protects against influenza illness.
    Langley JM, Aoki F, Ward BJ, McGeer A, Angel JB, Stiver G, Gorfinkel I, Shu D, White L, Lasko B, Dzongowski P, Papp K, Alexander M, Boivin G, Fries L.
    Vaccine; 2011 Feb 24; 29(10):1921-8. PubMed ID: 21219987
    [Abstract] [Full Text] [Related]

  • 29. Phase 4 randomized trial of intradermal low-antigen-content inactivated influenza vaccine versus standard-dose intramuscular vaccine in HIV-1-infected adults.
    Ansaldi F, Valle L, de Florentiis D, Parodi V, Murdaca G, Bruzzone B, Durando P, Setti M, Icardi G.
    Hum Vaccin Immunother; 2012 Aug 24; 8(8):1048-52. PubMed ID: 22832261
    [Abstract] [Full Text] [Related]

  • 30. Immunogenicity and safety of low dose virosomal adjuvanted influenza vaccine administered intradermally compared to intramuscular full dose administration.
    Künzi V, Klap JM, Seiberling MK, Herzog C, Hartmann K, Kürsteiner O, Kompier R, Grimaldi R, Goudsmit J.
    Vaccine; 2009 Jun 02; 27(27):3561-7. PubMed ID: 19464535
    [Abstract] [Full Text] [Related]

  • 31. Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group.
    Boonnak K, Dhitavat J, Thantamnu N, Kosoltanapiwat N, Auayporn M, Jiang L, Puthavathana P, Pitisuttithum P.
    Vaccine; 2017 Dec 19; 35(52):7339-7346. PubMed ID: 29157960
    [Abstract] [Full Text] [Related]

  • 32. Safety and immunogenicity of investigational seasonal influenza hemagglutinin DNA vaccine followed by trivalent inactivated vaccine administered intradermally or intramuscularly in healthy adults: An open-label randomized phase 1 clinical trial.
    Carter C, Houser KV, Yamshchikov GV, Bellamy AR, May J, Enama ME, Sarwar U, Larkin B, Bailer RT, Koup R, Chen GL, Patel SM, Winokur P, Belshe R, Dekker CL, Graham BS, Ledgerwood JE, VRC 703 study team.
    PLoS One; 2019 Dec 19; 14(9):e0222178. PubMed ID: 31532789
    [Abstract] [Full Text] [Related]

  • 33. Safety and immunogenicity of a prototype adjuvanted inactivated split-virus influenza A (H5N1) vaccine in infants and children.
    Nolan T, Richmond PC, Formica NT, Höschler K, Skeljo MV, Stoney T, McVernon J, Hartel G, Sawlwin DC, Bennet J, Ryan D, Basser RL, Zambon MC.
    Vaccine; 2008 Nov 25; 26(50):6383-91. PubMed ID: 18801398
    [Abstract] [Full Text] [Related]

  • 34. Immunogenicity and safety of Fluzone(®) intradermal and high-dose influenza vaccines in older adults ≥65 years of age: a randomized, controlled, phase II trial.
    Tsang P, Gorse GJ, Strout CB, Sperling M, Greenberg DP, Ozol-Godfrey A, DiazGranados C, Landolfi V.
    Vaccine; 2014 May 01; 32(21):2507-17. PubMed ID: 24120672
    [Abstract] [Full Text] [Related]

  • 35. Comparison of the immunogenicity and safety of a split-virion, inactivated, trivalent influenza vaccine (Fluzone®) administered by intradermal and intramuscular route in healthy adults.
    Frenck RW, Belshe R, Brady RC, Winokur PL, Campbell JD, Treanor J, Hay CM, Dekker CL, Walter EB, Cate TR, Edwards KM, Hill H, Wolff M, Leduc T, Tornieporth N.
    Vaccine; 2011 Aug 05; 29(34):5666-74. PubMed ID: 21699951
    [Abstract] [Full Text] [Related]

  • 36. A phase I evaluation of inactivated influenza A/H5N1 vaccine administered by the intradermal or the intramuscular route.
    Patel SM, Atmar RL, El Sahly HM, Cate TR, Keitel WA.
    Vaccine; 2010 Apr 09; 28(17):3025-9. PubMed ID: 19931380
    [Abstract] [Full Text] [Related]

  • 37. Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trial.
    Hoon Han S, Hee Woo J, Weber F, Joo Kim W, Ran Peck K, Il Kim S, Hwa Choi Y, Myung Kim J.
    Hum Vaccin Immunother; 2013 Sep 09; 9(9):1971-7. PubMed ID: 23778938
    [Abstract] [Full Text] [Related]

  • 38. Intanza(®): a new intradermal vaccine for seasonal influenza.
    Atmar RL, Patel SM, Keitel WA.
    Expert Rev Vaccines; 2010 Dec 09; 9(12):1399-409. PubMed ID: 21105776
    [Abstract] [Full Text] [Related]

  • 39. Dose sparing strategy with intradermal influenza vaccination in patients with solid cancer.
    Jo YM, Song JY, Hwang IS, Lee J, Oh SC, Kim JS, Kim SR, Kim WJ, Cheong HJ.
    J Med Virol; 2009 Apr 09; 81(4):722-7. PubMed ID: 19235853
    [Abstract] [Full Text] [Related]

  • 40. Immunization against influenza: comparison of various topical and parenteral regimens containing inactivated and/or live attenuated vaccines in healthy adults.
    Keitel WA, Cate TR, Nino D, Huggins LL, Six HR, Quarles JM, Couch RB.
    J Infect Dis; 2001 Jan 15; 183(2):329-332. PubMed ID: 11110645
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.